Total Funding
77
69
Total FundingSeries A raised
Growth Score 77 in past quarter
-3 pts
Heat Score 69 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
54906
StemInov develops stem cell therapies for inflammatory diseases, focusing on septic shock and ARDS.
- Danielle Bensoussan: Scientific Founder
- Julie Hutin: Co-Founder, Chief Executive Officer, and President
About the Company
StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. The
company is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC).